Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Leukemia 2Esophageal Neoplasms 2Adenocarcinoma Of Esophagus 2Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Prolactinoma 1Pituitary Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Large Granular Lymphocytic 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Growth Hormone-Secreting Pituitary Adenoma 1Gliosarcoma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Chondrosarcoma 1Central Nervous System Neoplasms 1

Interventions

Dexamethasone 337Bortezomib 187Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × Microarray Analysis × Clear all
NCT00567229 2015-11-20

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
3 enrolled 6 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01055301 2015-03-06

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡